Biogen Inc. SEC filings BIIB
Biogen Inc. has 1,001 filings in SEC EDGAR's recent list, going back to Oct 2, 2014. Its latest annual report, Form ARS, was filed on Apr 28, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Oct 28, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Oct 28, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| SC TO-T/A | Filing | May 14, 2026 | — |
| SC TO-T/A | Amendment no. 2 | May 12, 2026 | — |
| SC TO-T/A | Amendment no. 1 | May 6, 2026 | — |
| SC TO-T | Filing | Apr 14, 2026 | — |
| SC TO-C | Schedule to | Apr 7, 2026 | — |
| SC TO-C | Schedule to | Apr 3, 2026 | — |
| SC TO-C | Filing | Mar 31, 2026 | — |
| SC TO-C | Schedule to | Mar 31, 2026 | — |
| DEFR14A | Filing | Jun 13, 2023 | — |
| EFFECT | Filing | Jul 12, 2022 | — |
| EFFECT | Filing | May 26, 2022 | — |
| CORRESP | Letter to the SEC | May 24, 2022 | — |
| UPLOAD | Letter from the SEC | May 23, 2022 | — |
| UPLOAD | Letter from the SEC | Jun 22, 2021 | — |
| CORRESP | Letter to the SEC | Jun 21, 2021 | — |
| UPLOAD | Letter from the SEC | Jun 17, 2021 | — |
| CORRESP | Letter to the SEC | Jun 9, 2021 | — |
| PX14A6G | Filing | May 28, 2021 | — |
| UPLOAD | Letter from the SEC | May 13, 2021 | — |
| CORRESP | Letter to the SEC | Apr 7, 2021 | — |
| UPLOAD | Letter from the SEC | Mar 25, 2021 | — |
| UPLOAD | Letter from the SEC | Jul 23, 2018 | — |
| CORRESP | Letter to the SEC | Jun 28, 2018 | — |
| UPLOAD | Letter from the SEC | Jun 18, 2018 | — |
| PX14A6G | Filing | May 3, 2018 | — |
| PX14A6G | Filing | Mar 27, 2018 | — |
| UPLOAD | Letter from the SEC | May 25, 2017 | — |
| CORRESP | Letter to the SEC | May 10, 2017 | — |
| UPLOAD | Letter from the SEC | May 3, 2017 | — |
| CORRESP | Letter to the SEC | Apr 4, 2017 | — |
| UPLOAD | Letter from the SEC | Mar 23, 2017 | — |
| NO ACT | Auto-generated paper document | Feb 23, 2017 | Feb 16, 2017 |
| CT ORDER | Filing | Mar 29, 2016 | — |
Showing 33 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- BIIB (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Cambridge, MA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 875045
- Former names
- BIOGEN IDEC INC. (until Mar 20, 2015); BIOGEN IDEC INC (until Apr 25, 2007); IDEC PHARMACEUTICALS CORP / DE (until Nov 12, 2003); IDEC PHARMACEUTICALS CORP / CA (until Feb 14, 1997)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
- Neurocrine Biosciences Inc NBIX
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.